BRAIN Biotech AG - Asset Resilience Ratio
BRAIN Biotech AG (BNN) has an Asset Resilience Ratio of 9.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BRAIN Biotech AG short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how BRAIN Biotech AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of BRAIN Biotech AG.
Liquid Assets Composition Over Time
This chart breaks down BRAIN Biotech AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BRAIN Biotech AG (BNN) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.19 Million | 9.33% |
| Short-term Investments | €126.00K | 0.19% |
| Total Liquid Assets | €6.32 Million | 9.52% |
Asset Resilience Insights
- Limited Liquidity: BRAIN Biotech AG maintains only 9.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BRAIN Biotech AG Industry Peers by Asset Resilience Ratio
Compare BRAIN Biotech AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP |
Specialty Chemicals | 1.69% |
|
Cngr Advanced Material Co Ltd
SHE:300919 |
Specialty Chemicals | 0.52% |
|
Supreme Petrochem Limited
NSE:SPLPETRO |
Specialty Chemicals | 8.22% |
|
5N Plus Inc.
TO:VNP |
Specialty Chemicals | 12.56% |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930 |
Specialty Chemicals | 0.01% |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488 |
Specialty Chemicals | 1.39% |
|
Jiangxi Guotai Civilian
SHG:603977 |
Specialty Chemicals | 12.39% |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093 |
Specialty Chemicals | 25.17% |
Annual Asset Resilience Ratio for BRAIN Biotech AG (2012–2025)
The table below shows the annual Asset Resilience Ratio data for BRAIN Biotech AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 9.52% | €6.32 Million ≈ $7.38 Million |
€66.34 Million ≈ $77.55 Million |
-21.16pp |
| 2024-09-30 | 30.69% | €27.23 Million ≈ $31.83 Million |
€88.74 Million ≈ $103.74 Million |
+23.06pp |
| 2023-09-30 | 7.62% | €5.41 Million ≈ $6.32 Million |
€70.94 Million ≈ $82.93 Million |
-3.67pp |
| 2022-09-30 | 11.29% | €8.80 Million ≈ $10.29 Million |
€77.99 Million ≈ $91.18 Million |
-20.42pp |
| 2021-09-30 | 31.71% | €24.65 Million ≈ $28.82 Million |
€77.74 Million ≈ $90.88 Million |
+5.31pp |
| 2020-09-30 | 26.40% | €19.05 Million ≈ $22.27 Million |
€72.15 Million ≈ $84.35 Million |
+3.38pp |
| 2019-09-30 | 23.02% | €15.22 Million ≈ $17.80 Million |
€66.12 Million ≈ $77.30 Million |
-11.62pp |
| 2018-09-30 | 34.65% | €25.80 Million ≈ $30.16 Million |
€74.46 Million ≈ $87.06 Million |
-22.34pp |
| 2017-09-30 | 56.99% | €39.04 Million ≈ $45.64 Million |
€68.50 Million ≈ $80.09 Million |
+17.71pp |
| 2016-09-30 | 39.28% | €18.66 Million ≈ $21.82 Million |
€47.51 Million ≈ $55.55 Million |
+38.29pp |
| 2015-09-30 | 0.99% | €299.85K ≈ $350.55K |
€30.41 Million ≈ $35.55 Million |
-6.98pp |
| 2013-09-30 | 7.97% | €2.00 Million ≈ $2.34 Million |
€25.10 Million ≈ $29.34 Million |
-13.55pp |
| 2012-09-30 | 21.52% | €4.24 Million ≈ $4.96 Million |
€19.71 Million ≈ $23.04 Million |
-- |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more